Molecular Cancer Therapeutics Funding
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fang, Y.
Right arrow Articles by Abraham, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, Y.
Right arrow Articles by Abraham, R. T.
Vol. 2, 517-526, June 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

Characterization of the Cytotoxic Activities of Novel Analogues of the Antitumor Agent, Lavendamycin1

Yanan Fang, Corinne M. Linardic, D. Ashley Richardson, Wen Cai, Mohammad Behforouz and Robert T. Abraham2

Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710 [Y. F., C. M. L., D. A. R.]; Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710 [C. M. L.]; Department of Chemistry, Ball State University, Muncie, Indiana 47306 [W. C., M. B.]; and The Burnham Institute, La Jolla, California 92037 [R. T. A.]

Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities. However, preclinical development of lavendamycin as an anticancer agent was halted due to the poor aqueous solubility and relatively nonspecific cytotoxic activity of this compound. In this report, we have examined the cytotoxic activities of a series of novel lavendamycin analogues. The cytotoxic activities of these compounds were evaluated in clonogenic survival assays with A549 lung carcinoma cells. Compounds bearing an amide or amine substituent at the R3 position were the most potent inhibitors of colony formation. MB-97, the most active member of this subgroup, decreased clonogenic outgrowth by 70% at a concentration of 10 n. Treatment of A549 cells with MB-97 led to an increase in p53 protein expression and phosphorylation and a concomitant increase in the expression of the p53 target gene, p21. Exposure of p53-positive cells to MB-97 triggered cell cycle arrest in G1 and G2 phases but induced a selective G2-phase arrest in p53-negative cells. MB-97 treatment also induced a higher level of apoptosis in p53-null cells relative to their p53-positive counterparts. Finally, MB-97 showed significant cytotoxic activity in the National Cancer Institute’s panel of 60 cancer cell lines and antitumor activity in vivo in hollow fiber tumorigenesis assays.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. Choudhary and H.-C. R. Wang
Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells
Mol. Cancer Ther., March 1, 2007; 6(3): 1099 - 1111.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.